1-9 of 9
Clarissa Uhlar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

Niels W.C.J. van de Donk, Ajai Chari, Lionel Karlin, Amrita Y Krishnan, Katarina Uttervall, Thomas Chalopin, Laura Rosinol Dachs, Albert Oriol, Jeffrey V Matous, Manisha Bhutani, Cesar Rodriguez, Natalia A Quijano Cardé, Yue Guo, Caroline Hodin, Clarissa Uhlar, Tara Stephenson, Athena Zuppa, Margaret Doyle, Katherine Chastain, Alfred L Garfall
Journal: Blood
Blood (2024) 144 (Supplement 1): 4734.
https://doi.org/10.1182/blood-2024-200344
Published: 2024
Journal Articles

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Clinical Trials & Observations
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, Onsay Lau, Karl Calara-Nielsen, Cuc Davis, Jaymala Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Z. Usmani, Nizar J. Bahlis, Niels W. C. J. van de Donk, Raluca I. Verona
Journal: Blood
Blood (2024) 144 (6): 615–628.
https://doi.org/10.1182/blood.2023022823
Published: 2024
Includes: Supplemental data
Journal Articles

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Tatiana Perova, Onsay Lau, Cuc Davis, Yue Guo, Xin Miao, Tara Stephenson, Caroline Hodin, Clarissa Uhlar, Danielle Trancucci, Katherine Chastain, Nizar J Bahlis, Niels W.C.J. Van De Donk, Raluca Verona
Journal: Blood
Blood (2023) 142 (Supplement 1): 455.
https://doi.org/10.1182/blood-2023-173550
Published: 2023
Journal Articles

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius

Saad Z Usmani, MD, Hareth Nahi, Brendan M Weiss, MD, Nizar J. Bahlis, MD, Andrew Belch, Henk M Lokhorst, Peter M. Voorhees, MD, Paul G Richardson, MD, Clarissa Uhlar, Jianping Wang, Ming Qi, Sagar Lonial, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3107.
https://doi.org/10.1182/blood.V130.Suppl_1.3107.3107
Published: 2017
Journal Articles

Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab

Ajai Chari, MD, Toshihisa Satta, Amit Tayal, Sundar Jagannath, MD, Hearn Jay Cho, MD PhD, Samir Parekh, MD, Kenneth Lau, Gillian Morgan, Donna Catamero, Juliet Escalon, Erika Florendo, Daniel Verina, Parul Doshi, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Peter M. Voorhees, Maria-Victoria Mateos, Suzanne Arinsburg
Journal: Blood
Blood (2015) 126 (23): 3571.
https://doi.org/10.1182/blood.V126.23.3571.3571
Published: 2015
Journal Articles

Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)

Peter M. Voorhees, Brendan Weiss, Saad Usmani, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Sagar Lonial, MD
Journal: Blood
Blood (2015) 126 (23): 1829.
https://doi.org/10.1182/blood.V126.23.1829.1829
Published: 2015
Journal Articles

Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Saad Usmani, Brendan Weiss, Nizar J Bahlis, MD, Andrew Belch, Sagar Lonial, MD, Henk Lokhorst, Peter M. Voorhees, MD, Paul G. Richardson, A Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi
Journal: Blood
Blood (2015) 126 (23): 29.
https://doi.org/10.1182/blood.V126.23.29.29
Published: 2015
Journal Articles

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Clinical Trials & Observations
Jesús San-Miguel, Joan Bladé, Ofer Shpilberg, Sebastian Grosicki, Frédéric Maloisel, Chang-Ki Min, Marta Polo Zarzuela, Tadeusz Robak, Sripada V. S. S. Prasad, Yeow Tee Goh, Jacob Laubach, Andrew Spencer, María-Victoria Mateos, Antonio Palumbo, Tom Puchalski, Manjula Reddy, Clarissa Uhlar, Xiang Qin, Helgi van de Velde, Hong Xie, Robert Z. Orlowski
Journal: Blood
Blood (2014) 123 (26): 4136–4142.
https://doi.org/10.1182/blood-2013-12-546374
Published: 2014
Journal Articles

QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Sheeba K. Thomas, MD, Alexander Suvorov, MD, Lucien Noens, MD, PhD, Oleg Rukavitsin, MD, Joseph Fay, MD, Ka Lung Wu, MD, PhD, Todd M Zimmerman, MD, Helgi van de Velde, MD, PhD, Rajesh Bandekar, PhD, Thomas A Puchalski, PharmD, Ming Qi, MD, PhD, Clarissa Uhlar, PhD, Olga S Samoilova, MD
Journal: Blood
Blood (2012) 120 (21): 2972.
https://doi.org/10.1182/blood.V120.21.2972.2972
Published: 2012